catalysthcc.com
Catalyst Offers Insights on FDA and the Political Landscape During FDA/CMS Summit Panel Discussion
On Dec. 11, Catalyst President Nancy Bradish Myers spoke as part of a panel on changes in the political landscape impacting the biopharma industry at the FDA/CMS Summit in Washington, DC. Following Commissioner Gottlieb’s announcement of FDA action on biosimilars, and CDER Director Janet Woodcock’s presentation of her priorities for 2019, the panel focused